Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of PRM-151 (recombinant human Pentraxin-2 (PTX-2)) will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), being held May 1-5, 2011 in Ft. Lauderdale, FL. The data to be presented highlight the efficacy and utility of Pentraxin-2 in suppressing choroidal and retinal neovascularization in independent models of age-related macular degeneration (AMD) and diabetic retinopathy. Pentraxin-2 is a natural human protein that regulates the cell populations that control fibrosis, inflammation and pathologic neovascularization. In AMD and diabetic retinopathy, neovascularization is known to cause retinal damage which can result in visual impairment and progressive loss of vision.
The schedule and details of the poster presentation for PRM-151, recombinant human Pentraxin-2 (PTX-2), at ARVO is as follows:
Abstract Title: PRM-151, recombinant human Pentraxin-2 (PTX-2), Suppresses
Choroidal (CNV) and Retinal Neovascularization (RNV)
Session Title: AMD Preclinical and Translational Studies
Session Number: 412
Session Start: Wednesday, May 4, 2011, 8:30 AM -10:15 AM
Location: Hall B/C
Organizing Section: Retina+
Program #/Board #: 4000-4024/A138-A162
Breakthrough $20 million OCT project aims to revolutionize eye health screening